Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Pfizer Inc — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.55 (market cap $7.77B), while Pfizer Inc trades at $27.71 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 20.4× Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF's market cap, and Pfizer Inc pays a 6.18% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days and Pfizer Inc for 158 Days on average.
| PDBC | PFE | |
|---|---|---|
Market Cap | $7.77B | $158.56B |
Volume | 6,100,303 | 44,138,282 |
52-Week High | $20.10 | $29.02 |
52-Week Low | $13.16 | $23.67 |
Typical Hold Time | 56 Days | 158 Days |
Sector | — | Health |
Enterprise Value | — | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy ETF, trades at $19.41 with a slight 0.26% decline. Technical indicators show a neutral overall signal with bullish moving averages. The ETF has demonstrated strong performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodities amid geopolitical tensions. Recent institutional activity shows mixed signals with significant short interest growth alongside new institutional investments.
The outlook for PDBC remains tied to commodity market dynamics, with potential upside from continued geopolitical tensions and defensive portfolio shifts. However, risks include the 215% surge in short interest and commodity price volatility. The ETF offers exposure to broad commodities diversification but faces headwinds from potential market normalization.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
